Kiromic Biopharma Inc Total Liabilities
Kiromic Biopharma Inc total liabilities. Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has total liabilities worth $21.13 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See KRBP defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Kiromic Biopharma Inc (2018–2024)
Total liabilities of Kiromic Biopharma Inc from 2018 to 2024. This chart illustrates how Kiromic Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Kiromic Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Kiromic Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ImmuPharma PLC
LSE:IMM
|
UK | GBX1.24 Million |
|
UMT United Mobility Technology AG
XETRA:UMDK
|
Germany | €4.28 Million |
|
Gangotri Textiles Limited
NSE:GANGOTRI
|
India | Rs2.52 Billion |
|
TRELLUS HEALTH LS -0006
F:85Q
|
Germany | €513.00K |
|
Conygar Investment Co PLC
LSE:CIC
|
UK | GBX45.07 Million |
|
Rajvir Industries Limited
NSE:RAJVIR
|
India | Rs1.13 Billion |
|
Rua Life Sciences PLC
LSE:RUA
|
UK | GBX1.89 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Kiromic Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kiromic Biopharma Inc assets under control.
Liquidity & Leverage Metrics
Kiromic Biopharma Inc Total Liabilities Ratios Explained
Kiromic Biopharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kiromic Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual total liabilities of Kiromic Biopharma Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $21.13 Million | -0.74% |
| 2023-12-31 | $21.29 Million | +20.00% |
| 2022-12-31 | $17.74 Million | +420.33% |
| 2021-12-31 | $3.41 Million | +132.34% |
| 2020-12-31 | $1.47 Million | +117.84% |
| 2019-12-31 | $673.70K | +10.32% |
| 2018-12-31 | $610.70K | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more